Cohen Cheryl sold $851K of IBRX
Cohen Cheryl sold 81,056 shares of ImmunityBio, Inc. (IBRX) at $10.50 ($0.85M total) on 2026-10-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides fresh, primary‑source information about insider activity, which can influence short‑term price dynamics.
Market read
Insider sales are closely monitored; this filing may prompt traders to reassess short‑term positioning in IBRX.
What to watch
Potential upcoming clinical data releases or financing needs that prompted the sale.
Background
SEC Form 4 filing discloses a director's open‑market sale under a pre‑arranged 10b5‑1 plan.
Ticker impact
Director Cheryl Cohen sold 81,056 shares of ImmunityBio for $851,088 via a 10b5-1 plan, reducing her holdings to 100,309 shares.
likely slight downward pressure as the market prices in the insider sell.
Form 4 filings are primary source; a director sale of over $800k is material for a micro‑cap biotech and often triggers short‑term selling.
Market effects
May raise caution for other small‑cap biotech stocks as insider sales are watched closely.
Limited to U.S. biotech investors; no broader regional effect.
Minimal; impact confined to ImmunityBio and its immediate peer group.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- companyImmunityBio, Inc.
Biotech firm listed on NASDAQ (IBRX).
- personCheryl Cohen
Director of ImmunityBio who executed the sale.
